AMD is going head-to-head with Nvidia in AI-backed drug discovery with new deal
Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.
AMD invests $20M in AI-powered drug discovery company Absci
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort will place particular emphasis on developing technologies that can advance drug discovery.
AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips
The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries.
AMD to invest $20m in Absci to boost AI drug discovery tech
AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design models.
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads,
AMD invests $20 million in AI drug research at Vancouver-based Absci
Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies. Absci hopes artificial intelligence will enable it to move faster to develop protein-based medicines called biologics,
How a single nitrogen atom could transform the future of drug discovery
Researchers at the University of Oklahoma have developed a breakthrough method of adding a single nitrogen atom to molecules, ...
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
The deal extends an agreement to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease ...
Alloy Therapeutics Announces New Licensing Model for ATX-Gx™ Antibody Discovery Platform and Launches mAbForge™ High-Throughput Screening Service
Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
Will AI revolutionize drug development? Researchers explain why it depends on how it’s used
The potential of using artificial intelligence in drug discovery and development has sparked both excitementand skepticism ...
Virtual chemistry speeds up drug discovery
Among the hundreds of thousands of chemical compounds produced by plants, some may hold the key to treating human ailments and diseases. But recreating these complex, naturally occurring molecules in ...
The Prescription For Change: Five Ways Tech Can Improve Drug Pricing While Supporting Innovation
Drug pricing is influenced by numerous factors, but technology has the potential to strike the critical balance between ...
Novo Nordisk Expands Drug Discovery Collaboration With Valo Health For Cardiometabolic Diseases
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...
PostEra announces expansion to $610M in their AI drug discovery collaboration with Pfizer
PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with Pfizer. The parties will launch a new Antibody- ...